Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens

NCT00753545 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00753545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00753545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2008
Completion date
October 12, 2023
Enrollment
265 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer